Trademarking a shape of a product, or proving that a competitor is passing off their product as your own, is not easy. A high-profile settlement, though, is marketing gold.
Articles on Intellectual property
Displaying 41 - 60 of 154 articles
The new variant is a warning: unless we take urgent action to correct global vaccine inequities, we risk the emergence of further variants, some of which may evade vaccines.
South Africa has a stringent pharmaceutical regulatory framework. But this framework is not backed by a strong implementation strategy.
The path to using old drugs for COVID is full of potholes. So why are we using the same old flawed methods when we actually know what works?
There’s a difference between owning property and owning the copyright in that property.
Potential benefits of human genome editing include new ways to diagnose, treat and prevent genetic disorders. But there’s a significant gap in regulation.
The Federal Court of Australia has made a world-first ruling in favour of granting a patent to an artificial intelligence. But what comes next?
Relying on donor funding means that the funder ultimately determines the health priorities. This is one reason why many programmes in Africa focus on a single disease such as HIV.
The pharmaceutical industry overall has been deeply opposed to waiving COVID-19 vaccine patents, but a historian of the industry explains that drug companies once opposed patents altogether.
Small and medium-sized businesses play an important role in economic growth and development but are hamstrung by their lack of adequate resources to market their goods and services.
Lowering the tax rates on profits from patents registered in Australia is unlikely to increase local research and development. But it will be a gift for multinationals.
Waiver talks might convince companies to focus on technology transfer and training, and let go of the plan to maximise patent-based revenues.
Much remains to be resolved before the waiver is translated into increased vaccine supply.
Despite some public virtue signalling, the Canadian government is not doing all it can to improve global access to COVID-19 vaccines. Canada has yet to announce its position on the WTO patent waiver.
The US has backed a proposal to waive intellectual property relating to COVID measures – but global efforts need to go beyond vaccine patents.
Various strategies are being pursued to boost worldwide vaccine coverage.
The change in the US position signals how clearly the success of every country in fighting the pandemic depends on vaccinating the whole world.
It’s not clear whether the TRIPS agreement is what’s getting in the way of vaccine supply, and waiving intellectual property rights may stifle future innovation.
Increasing skills and the availability of raw materials would be a bigger boost for vaccine production right now.
Pfizer and Moderna are expected to make billions in revenue this year. It’s time all vaccine producers share their IP, data and know-how with the rest of the world.
Top contributors
-
Professor of Intellectual Property Law, City St George's, University of London
-
Professor of Public Health, La Trobe University
-
Professor in Intellectual Property and Innovation Law, Queensland University of Technology
-
Professor of Law, University of Sydney
-
Associate Professor, School of Law, University of Canberra
-
Associate Vice President for Entrepreneurship and Innovation, Clemson University
-
Associate professor, University of Canterbury
-
Professor of Law, University of Melbourne; Chair of Private Law, Te Herenga Waka — Victoria University of Wellington
-
Professor and Distinguished Research Chair, Globalization and Health Equity, L’Université d’Ottawa/University of Ottawa
-
Distinguished Professor, Arthur J. Gosnell Professor of Economics, & Head, Department of Sustainability, Rochester Institute of Technology
-
Director, Melbourne Institute of Applied Economic and Social Research, The University of Melbourne
-
Professor in International Relations / International Political Economy, UNSW
-
Senior Lecturer in Biochemistry and Cell Biology, University College Cork
-
Professor, University of Gondar
-
ARC Future Fellow; Professor; Director, Intellectual Property Research Institute of Australia, The University of Melbourne